Baidu
map

Chest:结核病合并糖尿病的流行病学和临床管理

2017-04-25 MedSci MedSci原创

目前,研究者们对2型糖尿病(DM)和结核病(TB)之间的相互作用越来越感兴趣,但许多研究问题仍然没有得到解决。流行病学家、基础科学家和临床专家最近召集并确定了优先事项。近期,有关流行病学、临床管理和公共卫生优先研究领域的相关认识发表在杂志Chest上。首先,从流行病学的角度来看,需要更多的研究来确定结核病患者发生暂时性高血糖的重要性,以及DM对全球多药耐药(MDR)-TB流行的重要性。第二,关于合

目前,研究者们对2型糖尿病(DM)和结核病(TB)之间的相互作用越来越感兴趣,但许多研究问题仍然没有得到解决。


流行病学家、基础科学家和临床专家最近召集并确定了优先事项。近期,有关流行病学、临床管理和公共卫生优先研究领域的相关认识发表在杂志Chest上。

首先,从流行病学的角度来看,需要更多的研究来确定结核病患者发生暂时性高血糖的重要性,以及DM对全球多药耐药(MDR)-TB流行的重要性。

第二,关于合并TB-DM疾病的筛查和临床管理,临床试验和大型队列研究应评估改善DM以及TB长期或加强治疗后对TB-DM结局的好处,同时还应调查在新诊断的结核病患者中筛查DM方法的成本效益。

第三,从公共卫生和卫生系统的角度来看,应该考察在高负担人群中,对DM和TB的不同干预措施对人群健康影响和成本效益;同时应该制定卫生系统干预措施以便进行DM筛查、TB治疗完成后管理DM,以及更好地获得全球性的DM服务。鉴于代谢紊、炎症反应、药物和获得保健的异质性,需要对不同种族和环境进行研究。

最后,由于撒哈拉以南非洲和世界其他地区的流行病趋同,应该解决结核病、糖尿病和艾滋病毒之间的相互作用。

原始出处:
Critchley JA, Restrepo BI, et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes. Part 1: Epidemiology and clinical management. Chest. 2017 Apr 19. pii: S0012-3692(17)30730-4. doi: 10.1016/j.chest.2017.04.155.  

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050658, encodeId=2f10205065887, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Feb 04 16:08:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929319, encodeId=0a92192931965, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 10 07:08:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192439, encodeId=78e0192439c0, content=学习了,谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 01 08:27:32 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254053, encodeId=c44d1254053d5, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411259, encodeId=83f11411259af, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487065, encodeId=88d3148e06539, content=<a href='/topic/show?id=2b902295e5b' target=_blank style='color:#2F92EE;'>#临床管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22957, encryptionId=2b902295e5b, topicName=临床管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d89d8256855, createdName=shuangle, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050658, encodeId=2f10205065887, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Feb 04 16:08:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929319, encodeId=0a92192931965, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 10 07:08:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192439, encodeId=78e0192439c0, content=学习了,谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 01 08:27:32 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254053, encodeId=c44d1254053d5, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411259, encodeId=83f11411259af, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487065, encodeId=88d3148e06539, content=<a href='/topic/show?id=2b902295e5b' target=_blank style='color:#2F92EE;'>#临床管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22957, encryptionId=2b902295e5b, topicName=临床管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d89d8256855, createdName=shuangle, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-08-10 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050658, encodeId=2f10205065887, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Feb 04 16:08:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929319, encodeId=0a92192931965, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 10 07:08:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192439, encodeId=78e0192439c0, content=学习了,谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 01 08:27:32 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254053, encodeId=c44d1254053d5, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411259, encodeId=83f11411259af, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487065, encodeId=88d3148e06539, content=<a href='/topic/show?id=2b902295e5b' target=_blank style='color:#2F92EE;'>#临床管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22957, encryptionId=2b902295e5b, topicName=临床管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d89d8256855, createdName=shuangle, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-05-01 大爰

    学习了,谢谢分享!!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2050658, encodeId=2f10205065887, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Feb 04 16:08:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929319, encodeId=0a92192931965, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 10 07:08:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192439, encodeId=78e0192439c0, content=学习了,谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 01 08:27:32 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254053, encodeId=c44d1254053d5, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411259, encodeId=83f11411259af, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487065, encodeId=88d3148e06539, content=<a href='/topic/show?id=2b902295e5b' target=_blank style='color:#2F92EE;'>#临床管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22957, encryptionId=2b902295e5b, topicName=临床管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d89d8256855, createdName=shuangle, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2050658, encodeId=2f10205065887, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Feb 04 16:08:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929319, encodeId=0a92192931965, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 10 07:08:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192439, encodeId=78e0192439c0, content=学习了,谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 01 08:27:32 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254053, encodeId=c44d1254053d5, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411259, encodeId=83f11411259af, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487065, encodeId=88d3148e06539, content=<a href='/topic/show?id=2b902295e5b' target=_blank style='color:#2F92EE;'>#临床管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22957, encryptionId=2b902295e5b, topicName=临床管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d89d8256855, createdName=shuangle, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-04-27 xugumin
  6. [GetPortalCommentsPageByObjectIdResponse(id=2050658, encodeId=2f10205065887, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Feb 04 16:08:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929319, encodeId=0a92192931965, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 10 07:08:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192439, encodeId=78e0192439c0, content=学习了,谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 01 08:27:32 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254053, encodeId=c44d1254053d5, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411259, encodeId=83f11411259af, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487065, encodeId=88d3148e06539, content=<a href='/topic/show?id=2b902295e5b' target=_blank style='color:#2F92EE;'>#临床管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22957, encryptionId=2b902295e5b, topicName=临床管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d89d8256855, createdName=shuangle, createdTime=Thu Apr 27 08:08:00 CST 2017, time=2017-04-27, status=1, ipAttribution=)]

相关资讯

世界防治结核病日,你该知道的事:结核病相关指南全新中文版大放送!!!

2017年是以“联合起来消除结核病”为主题的两年期世界防治结核病日活动的第二年。世卫组织今年将特别关注针对“不让任何人掉队”做出的联合努力,包括为解决耻辱感、歧视和边缘化以及为消除治疗障碍所采取的行动。梅斯小编为大家整理了结核病预防、诊断、管理,合并疾病处理,儿童结核相关的中文版指南,希望能为结核病的防治贡献一份力量!   一、结核病预防、诊断、管理相关指南&nb

世界防治结核病日 连续咳嗽半月需重视!

今天,是第22个世界防治结核病日。在大家印象中,结核病早已成为过去。但全国第五次结核病流行病学现场调查结果显示,中国当时有超过500万名结核病活动性患者,而感染结核病菌的人数为5.5亿人。5.5亿人感染了结核病菌,这一数字难免让人看得心惊肉跳。值得庆幸的是,感染了结核菌,并不意味着一定会成为结核病患者。人体感染结核菌后,大约5%~10%最终会出现结核病。目前,全球每年新出现结核病人800~10

3·24世界防治结核病日,这些知识你该知道!

2017年3月24日是世界防治结核病日,也就是明天,今年的主题是“联合起来消除结核病:不让任何人掉队”。世界防治结核病日由来1995年底世界卫生组织(WHO)将每年3月24日作为世界防治结核病日(World Tuberculosis Day),是为了纪念1882年德国微生物学家罗伯特?科霍向一群德国柏林医生发表他对结核病病原菌的发现。以提醒公众加深对结核病的认识。结核病由经常感染肺部的细菌(结核分

PNAS:美研究人员研制出新型血检,可快速诊断结核病仅需两个半小时

美国研究人员3月27日在美国《国家科学院学报》上报告说,他们研制出一种新型血液检测方法,仅需两个半小时就能诊断结核病,并快速判断病人的治疗情况。这项成果可能有助改善结核病诊断方法。据世界卫生组织估计,全球每年有约1000万人患结核病,约200万人因结核病死亡,其中许多人死亡的原因是未得到诊断或确诊太晚以致无法治愈。全球有三分之一的人感染结核杆菌却并不发病,其中约10%的人最终会患上结核病。因此,研

世界防治结核病日 连续咳嗽半月需重视

今天,是第22个世界防治结核病日。在大家印象中,结核病早已成为过去。但全国第五次结核病流行病学现场调查结果显示,中国当时有超过500万名结核病活动性患者,而感染结核病菌的人数为5.5亿人。

结核病日:看看带泥土味的结核病研究数据是怎么做出来的

3月24日是世界防治结核病日,结核病是全球十大死因之一,严重威胁着人类健康。在控制结核病的征程上,科研人员从未停步,他们用带着泥土味的研究数据努力书写中国结核病防治的未来之路。

Baidu
map
Baidu
map
Baidu
map